Patent · US Active

Crystalline form of [3-(4,5-dihydro-3-isoxazolyl)-2-methyl-4-(methylsulfonyl)phenyl]-(5-hydroxy-1-methyl-1H-pyrazol-4-yl)methanone

US8017556B2 · kind B2 · utility

3Cited by

4References

9Claims

0Family size

Assignee

BASF SE

Inventors

Joachim Gebhardt · Monsheim, DE
Peter Erk · Bischofswerda, DE
Heidi Emilia Saxell · Hallenberg, DE
Thomas Kroehl · Schriesheim, DE
Matthias Bratz · Schifferstadt, DE

Key dates

Filing date	Jul 4, 2008
Grant date	Sep 13, 2011
Priority date	—
Expiry date	Sep 15, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/10
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention relates to crystalline forms of [3-(4,5-dihydro-3-isoxazolyl)-2- methyl-4-(methylsulfonyl)phenyl]-(5-hydroxy-1-methyl-1 H-pyrazol-4-yl)methanone, which is also known under the common name topramezone. The invention also relates to a process for the preparation of these crystalline forms and formulations for plant protection which comprise one of these crystalline forms of topramezone.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.